Abstract:Objective: To study the application value of echocardiography dot tracking in the cardiotoxicity monitoring of anthracycline chemotherapy drugs. Methods: This is a retrospective analysis. The study subjects were 50 breast cancer patients admitted to the hospital from January 2018 to January 2020, who were treated with anthracycline chemotherapy drugs for 4 cycles before undergoing 12-lead ECG examination. According to the results, they were divided into a normal ECG group (25 cases) and an abnormal ECG group (25 cases). At the same time, 25 healthy women for physical examination during the same period were selected as the control group. All three groups had conventional echocardiographic examinations, related parameters were measured, two-dimensional speckle tracking imaging technology was selected to measure biomechanical parameters, and the three groups of conventional echocardiographic parameters and two-dimensional speckle tracking imaging technology related parameters were compared. Results: Compared with the normal ECG group and the control group, the E/A ratio of the abnormal ECG group was lower, and LVEDV was higher (P<0.05); compared with the control group, the PSD of the normal ECG group was higher, and the GLS, aLS, mLS, bLS, GRS, LV-Ptw, and AP-Prot were lower (P<0.05); compared with the normal ECG group and the control group, the PSD of the abnormal ECG group was higher, and GLS, aLS, mLS, bLS, GRS, GCS, LV-Ptw, AP-Prot were lower (P<0.05). Conclusion: The effect of echocardiographic spot tracking technology in the early monitoring of cardiotoxicity caused by anthracycline chemotherapeutics is better than conventional echocardiography. Observing the longitudinal myocardial activity of the left ventricle is helpful for evaluating early cardiac systolic dysfunction.